Depsipeptide (FK228) inhibits growth of human prostate cancer cells

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 2, 2008, Pages 182-189

  Lai, Ming Tsung ^a,b   Yang, Chuan Ching ^a   Lin, Tsai Yun ^a   Tsai, Fuu Jen ^c,d   Chen, Wen Chi ^c,e  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

FK228; Histone deacetylase inhibitor; Lung metastasis; Prodrug; Prostate adenocarcinoma; Prostate specific antigen

Indexed keywords

DEPSIPEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN P21; ROMIDEPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN 22RV1; CELL STRAIN PC 3; CHROMATIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG; MALE; METASTASIS; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS;

EID: 39649083125     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.01.020     Document Type: Article

References (14)

1. Rosato R.R., and Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2 (2003) 30-37
2. Weidle U.H., and Grossmann A. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20 (2000) 1471-1485
3. Arts A., de Schepper S., and Van Emelen K. Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10 (2003) 2343-2350
4. Ripple G.H., and Wilding G. Drug development in prostate cancer. Semin Oncol 26 (1999) 217-226
5. Wolffe A. Sinful repression. Nature 387 (1997) 16-17
6. Cairns B.R. Emerging roles for chromatin remodeling in cancer biology. Trends Cell Biol 11 (2001) S15-S21
7. Sadar M.D., and Gleave M.E. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 60 (2000) 5825-5831
8. Nudelman A., Levovich I., Cutts S.M., et al. The role of intracellularly released formaldehyde and butyric acid, in the anticancer activity of acyloxyalkyl esters. J Med Chem 48 (2005) 1042-1054
9. Butler L.M., Agus D.B., Scher H.I., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 (2000) 5165-5170
10. Chu K.C., Tarone R.E., and Freeman H.P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97 (2003) 1507-1516
11. Sandor V., Bakke S., Robey R.W., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8 (2002) 718-728
12. Byrd J.C., Marcucci G., Parthun M.R., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
13. Stadler W.M., Margolin K., Ferber S., et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 5 (2006) 57-60
14. Piekarz R.L., Frye A.R., Wright J.J., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12 (2006) 3762-3773